Table 1 Clinical characteristics of study patients.
From: Prognostic values of novel biomarkers in patients with AL amyloidosis
No. of patients | N = 73 |
|---|---|
Age (years) | 60 ± 10 |
Men, n (%) | 44 (60) |
Lambda light chain, n (%) | 56 (76%) |
Amyloid organ involvement, n (%) | |
Heart | 50 (68.5) |
Kidney | 41 (56.2) |
Gastrointestinal tract | 16 (21.9) |
Peripheral nerve | 27 (36.9) |
Revised Mayo staging, n (%) | |
I | 14 (19.2) |
II | 12 (16.4) |
III | 13 (17.8) |
IV | 34 (46.6) |
LA volume index (mL/m2) | 41.0 ± 13.5 |
E′ (cm/s) | 5.01 ± 1.82 |
E/E′ | 19.3 ± 2.00 |
Mean LV wall thickness (mm) | 11.6 ± 0.31 |
LV ejection fraction (%) | 59.3 ± 1.3 |
NT-proBNP (pg/mL) | 2141 (327.2–6746.5) |
Troponin T (ng/mL) | 0.051 (0.019–0.093) |
Creatinine (mg/dL), | 0.89 (0.71–1.11) |
eGFR (mL/min/1.73 m2) | 79.6 (58.9–94) |
Free light chain difference (mg/mL) | 309.0 (133.1–726.9) |
Autologous stem cell transplantation, n (%) | 20 (27%) |
